CJC-1295 for Sleep: Off-Label Evidence Summary

HealthRX.com

No study has tested CJC-1295 for sleep

Print or save as PDF

Key numbers

  • 5.8 to 8.1 daysEstimated half-life of the CJC-1295 DAC form after one subcutaneous injectionSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 20.2%Share of the night spent in slow-wave sleep after native GHRH, small male study (placebo 14.0%)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 63%Headache rate in the first Teichman trial, treated subjects (placebo 14%)Source: fda.gov, as cited Nov 7, 2026

See the public record for CJC-1295

At a glance

  • FDA status / Not approved; FDA found no approved product containing any form of CJC-1295 in 12 countries or through the EMA [1]
  • Sleep studies of CJC-1295 / None identified; FDA found only three published human studies, all of the DAC form in healthy volunteers [1]
  • Closest sleep data / Sleep-EEG trials of native GHRH in 7 to 13 volunteers [4][5]
  • Half-life of the DAC form / 5.8 to 8.1 days after one subcutaneous dose [6]
  • Hormone effect / Mean GH up 2- to 10-fold for 6 days or more; IGF-I up 1.5- to 3-fold for 9 to 11 days [6]
  • Reported side effects / Injection-site reactions, headache (63% vs 14% on placebo in the first Teichman study), flushing and transient low blood pressure [1]
  • Sport / Named by WADA; prohibited at all times [7]

Does CJC-1295 improve sleep?

There is no direct evidence. FDA identified only three published human studies of CJC-1295, all of the DAC form and all in healthy volunteers [1]. The two with available results, Teichman 2006 and Ionescu and Frohman 2006, measured growth hormone and IGF-I rather than sleep [6][2]. FDA found no study of any form of CJC-1295 in people with a disease [1].

The idea that it might help sleep comes from users rather than trials: in an analysis of 23 online forum threads about women's use of CJC-1295, improved sleep was one of the reasons posters gave for taking it [8]. A 2026 review described therapeutic peptides broadly as promising in preclinical work while noting a current lack of clinical trials; it listed CJC-1295 among growth hormone secretagogues [9].

Where the sleep idea comes from

Growth hormone is released in pulses, and in young adults the largest pulse comes shortly after sleep onset, during the first period of slow-wave sleep. In men, about 70% of the daily GH output occurs during early sleep [10]. Slow-wave sleep and GH secretion rise and fall together, and the review describing that relationship says studies most consistently indicate that GHRH promotes non-REM and/or slow-wave sleep through central rather than peripheral mechanisms [10].

The GHRH sleep trials used native GHRH, in small numbers, with intravenous dosing timed to the night.

Steiger 1992: seven men, four GHRH boluses

Seven male controls received placebo, 50 micrograms of GHRH, or 50 micrograms of somatostatin as four boluses at 22:00, 23:00, 24:00 and 01:00. Slow-wave sleep took up 20.2% of the night after GHRH (SD 6.6) compared with 14.0% after placebo (SD 5.6), and mean plasma GH rose to 10.8 ng/ml versus 3.2 ng/ml on placebo [4]. Nocturnal cortisol secretion was blunted after GHRH [4].

Kerkhofs 1993: timing changed the result

A single 0.3 microgram/kg GHRH bolus given in early sleep did not change slow-wave sleep but increased REM sleep. Given during the third REM period, it produced a marked decrease in wake and an almost 10-fold increase in slow-wave sleep; given after sleep deprivation until 04:00, it shortened wake [3]. The authors concluded that GHRH has sleep-promoting effects in young adults, particularly when given at a time of decreased sleep propensity [3].

Guldner 1997: 13 older adults

Thirteen healthy seniors (5 women, 8 men, mean age 69.3) received 4 x 50 micrograms of GHRH or placebo intravenously. Nocturnal awakenings fell and the first non-REM sleep period lengthened; the authors described the effect as much smaller than in young subjects, and cortisol was unchanged [5].

What this does and does not tell you about CJC-1295

Three differences matter.

Duration. CJC-1295 DAC binds albumin, so one subcutaneous injection has an estimated half-life of 5.8 to 8.1 days. Mean GH rose 2- to 10-fold for 6 days or more and IGF-I rose 1.5- to 3-fold for 9 to 11 days; after repeated doses IGF-I stayed above baseline for up to 28 days [6]. The GHRH sleep studies used native GHRH, given as timed boluses [3][4], and the short half-life of native GHRH limits its therapeutic use [2][6].

Pulsatility. A common worry is that constant stimulation would flatten GH pulses. In a single-injection study, a week after one 60 or 90 microgram/kg injection, GH pulse frequency and size were unchanged while trough GH rose about 7.5-fold, mean GH 46% and IGF-I 45% [2]. Neither this study nor Teichman 2006 reports a sleep outcome [6][2].

Dose. The published human doses were single subcutaneous injections of about 30 to 250 micrograms/kg, or two to three doses given weekly or every two weeks [1][6]. These are study doses, not recommendations.

What was reported in the human studies

Teichman 2006 ran two randomized, placebo-controlled, double-blind, ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61 [6]. Per FDA's summary of those trials: injection-site reactions in about 70% of treated subjects in the first study and in all treated subjects in the second; headache in 63% versus 14% on placebo and flushing, warmth and transient low blood pressure in about 30% of treated subjects (first study); transient diarrhea; and transient dizziness with low blood pressure in two subjects. Most events were more common at 125 or 250 micrograms/kg, and no serious adverse reactions were reported [1].

In the single-dose study by Ionescu and Frohman, 60 or 90 micrograms/kg produced dose-dependent increases in heart rate and transient injection-site redness and tenderness, with no serious adverse events [1].

Three safety points sit outside those trials:

  • FDA lists 'serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction' among its concerns, and states that available clinical data are limited [11].
  • FDA's briefing says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. FDA cites news reports that the person had chest discomfort 2 hours after an 11th weekly dose, that an ECG showed an acute heart attack, and that the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture; the data were never published, so a causal link is neither shown nor excluded [1].
  • GH and IGF-I elevation carries the risks listed on approved growth hormone labels, such as glucose intolerance and diabetes, fluid retention and tumor growth concerns. FDA describes the human CJC-1295 studies as short, small and mostly single-dose, so long-term safety is unknown [1].

Regulatory status and what is sold online

CJC-1295 has never been approved. FDA's December 2024 review found no approved product containing any form of CJC-1295 in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain or the United Kingdom, and none authorized by the European Medicines Agency [1].

FDA's page on bulk substances that may raise significant safety risks when compounded lists CJC-1295 in its 'nominated but withdrawn' table: it was in category 2 but came off because the nominators withdrew their nominations, and FDA's safety concerns remain posted [11]. CJC-1295 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is not on the list for outsourcing facilities (updated March 21, 2025); it is not a component of an FDA-approved drug and has no USP monograph [12][13]. FDA's reviewers proposed in December 2024 that none of its forms be added to the pharmacy bulks list, and on December 4, 2024 the Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [14]. CJC-1295 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [15].

FDA notes that CJC-1295 sold online is mostly labeled 'research use only', including blends with ipamorelin and GHRPs, and that it has turned up in illicit sports use [1]. WADA names CJC-1295 in section S2.2.4 as a growth hormone-releasing hormone analogue and prohibits it at all times, in and out of competition [7][16].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Which statement about CJC-1295 and sleep does the article support?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Frequently asked questions

Has any study tested CJC-1295 for sleep?
No published sleep study is identified. FDA found only three published human studies of CJC-1295, all of the DAC form and all in healthy volunteers [1]; the two with available results measured growth hormone and IGF-I rather than sleep [6][2]. Forum posts name better sleep as a reason for using it, which is not trial evidence [8].
Does GHRH increase deep sleep?
In small sleep-EEG studies of native GHRH (not CJC-1295) it shifted sleep staging. Four 50 microgram boluses raised slow-wave sleep from 14.0% to 20.2% of the night in seven men [4]. A single 0.3 microgram/kg bolus in early sleep did not change slow-wave sleep but increased REM sleep, while the same dose in the third REM period produced an almost 10-fold rise in slow-wave sleep [3].
Do the with-DAC and without-DAC forms differ for sleep?
No sleep study of either form is identified. FDA describes CJC-1295 as a 29-amino-acid GHRH analogue and CJC-1295 DAC as the same peptide with an added unit that lets it bind albumin and last much longer [1]. Only the DAC form has published human studies [1].
What side effects appeared in the CJC-1295 trials?
In the two Teichman trials: injection-site reactions in about 70% of treated subjects in the first study and in all treated subjects in the second, headache in 63% versus 14% on placebo and flushing and transient low blood pressure in about 30% (first study), transient diarrhea, and dizziness with low blood pressure in two subjects; no serious adverse reactions were reported [1]. A single-dose study saw dose-dependent heart rate increases [1].
Is CJC-1295 approved or available by compounding?
It is not approved; FDA found no approved product containing any form of CJC-1295 in 12 countries or through the EMA [1]. It is in none of the three categories on FDA's list for state-licensed pharmacies and is absent from the outsourcing facilities list [12][13], and the Pharmacy Compounding Advisory Committee voted against adding each form in December 2024 [14].
Is CJC-1295 banned in sport?
Yes. WADA's 2026 Prohibited List names CJC-1295 in S2.2.4 as a growth hormone-releasing hormone analogue, prohibited at all times, in and out of competition [7]; it is also named in the 2027 list [16].

References

Show all 18 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
  3. Kerkhofs M, Van Cauter E, Van Onderbergen A, Caufriez A, Thorner MO, Copinschi G. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J Physiol. 1993;264(4 Pt 1):E594-8.
  4. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(4):566-73.
  5. Guldner J, Schier T, Friess E, Colla M, Holsboer F, Steiger A. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging. 1997;18(5):491-5.
  6. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  7. World Anti-Doping Agency.
  8. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016;51(1):73-84.
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1).
  10. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep. 1998;21(6):553-66.
  11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  12. U.S. Food and Drug Administration.
  13. U.S. Food and Drug Administration.
  14. U.S. Food and Drug Administration.
  15. Official web page.
  16. World Anti-Doping Agency.
  17. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(3):191-204.
  18. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349.
Evidence overview for CJC-1295 for Sleep: Off-Label Evidence Summary